Menu

Manipulative Microbiomes

Gut bacteria control tumor growth via the mammalian immune system.

Apr 1, 2015
Jenny Rood

CANCER COMMAND: The microbiome (as puppeteer) affects the immune system’s influence on tumor growth, in tandem with inflammatory cytokines (dogs).ILLUSTRATION BY MELANIE R. RUTKOWSKI AND GRAPHIC DESIGN BY SUBTERRANEAN GRAFIX

EDITOR'S CHOICE IN CELL & MOLECULAR BIOLOGY

The paper
M.R. Rutkowski et al., “Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation,” Cancer Cell, 27:27-40, 2015.

The polymorphism
The gut microbiome influences nonintestinal cancer progression, but the role of toll-like receptor 5 (TLR5), an immune system protein that recognizes commensal bacteria, was a mystery. As more than seven percent of people have nonfunctional TLR5, José Conejo-Garcia of the Wistar Institute in Philadelphia and colleagues explored how TLR5 impacts tumor growth.

The controller
In a mouse model of sarcoma, the researchers found that tumors grew much faster in wild-type mice than in TLR5-deficient ones. Wiping out the mice’s microbiomes diminished the disparity, indicating that TLR5’s tumor-promoting effects are driven by commensal bacteria. TLR5-dependent signaling triggered the production of inflammatory interleukin 6 (IL-6), which in turn activated an immunosuppressive cascade—not switched on in TLR5-deficient animals—that promoted tumor growth.

The twist
In human breast cancers or mouse mammary carcinomas, where IL-6 levels are much lower, TLR5 had the opposite effect. Tumors in TLR5-deficient mice grew better, due to the upregulation of IL-17, a different inflammatory cytokine. As in the sarcoma model, any differences between TLR5-deficient and wild-type mice disappeared upon antibiotic treatment. “Cancer is a systemic disease that is very dramatically influenced by commensal bacteria,” Conejo-Garcia says.

The manipulation
“It’s very exciting to see this kind of progress,” says Susan Erdman of MIT. She says looking into the effects of human polymorphisms such as TLR5 “really contributes to the concept of personalized medicine in cancer therapy.” As a first step toward future treatments, study coauthor Melanie Rutkowski is exploring how manipulating the microbiome could inhibit tumor growth.

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing